Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00061958
Other study ID # NCI-2012-02534
Secondary ID DM02-172N01CM170
Status Terminated
Phase Phase 2
First received June 5, 2003
Last updated January 22, 2013
Start date June 2003

Study information

Verified date January 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well arsenic trioxide works in treating patients with metastatic or unresectable cancer of the esophagus or gastroesophageal junction. Drugs used in chemotherapy such as arsenic trioxide use different ways to stop tumor cells from dividing so they stop growing or die


Description:

OBJECTIVES:

I. Determine the response rate and duration of response in patients with advanced adenocarcinoma of the esophagus or gastroesophageal junction treated with arsenic trioxide.

II. Determine the toxicity of this drug in these patients.

OUTLINE: This is an open-label study.

Patients receive a loading dose of arsenic trioxide IV over 2 hours on days 1-5 on week 1. Beginning on week 2, patients receive a maintenance dose of arsenic trioxide IV twice weekly thereafter. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) continue to receive therapy for at least 6 months beyond CR.

Patients are followed every 3 months for 6 months or until disease progression.


Recruitment information / eligibility

Status Terminated
Enrollment 50
Est. completion date
Est. primary completion date April 2005
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed adenocarcinoma of the esophagus or gastroesophageal junction

- Metastatic or unresectable local-regional disease

- Osseous metastasis as the only site of disease not eligible

- Measurable disease

- Mediastinal or hilar lymph nodes must be at least 2.0 cm in diameter by CT scan or MRI to be considered measurable

- No known brain metastases

- Performance status - Zubrod 0-2

- Performance status - Karnofsky 60-100%

- At least 12 weeks

- Absolute granulocyte count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- Hemoglobin at least 8 g/dL

- Bilirubin no greater than 1.5 mg/dL

- SGOT and/or SGPT no greater than 2.0 times upper limit of normal (ULN)

- Creatinine no greater than 1.5 times ULN

- Creatinine clearance at least 60 mL/min

- Calcium no greater than 12 mg/dL

- No symptomatic hypercalcemia under treatment

- No New York Heart Association class III or IV heart disease

- No angina within the past 6 months

- No myocardial infarction within the past 6 months

- No congestive heart failure within the past 6 months

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No other concurrent active malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix

- Prior malignancies with no evidence of disease for at least 2 years are allowed

- No serious concurrent infection that is uncontrolled or whose control could be jeopardized by complications of study therapy

- No concurrent nonmalignant medical illness that is uncontrolled or whose control could be jeopardized by complications of study therapy

- No psychiatric disorder or other condition that would preclude study compliance

- No prior immunotherapy (including adjuvant or preoperative regimens)

- No concurrent biological response modifiers

- No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)

- No prior chemotherapy (including adjuvant or preoperative regimens and radiosensitizers)

- At least 4 weeks since prior radiotherapy and recovered

- No prior radiotherapy to major bone marrow containing areas (e.g., pelvis or lumbar spine) or area that contained the indicator lesion

- No prior radiotherapy involving 30% or more of the bone marrow

- No concurrent radiotherapy

- At least 2 weeks since prior major surgery (4 days for minor surgery) and recovered

- No other concurrent investigational drugs

- No other concurrent antineoplastic therapy

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
arsenic trioxide
Given IV

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response (OR) defined as a complete or partial remission, evaluated using RECIST criteria 8 weeks No
Secondary Duration of response From the time measurement criteria are met for CR or PR until the first date that recurrent or progressive disease is objectively documented, assessed up to 6 months No
Secondary Toxicity graded according to the Common Toxicity Criteria version 2 Up to 6 months Yes
See also
  Status Clinical Trial Phase
Terminated NCT01705340 - Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery Phase 1
Terminated NCT01249443 - Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Phase 1
Completed NCT01612546 - Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery Phase 2
Withdrawn NCT02344810 - C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer Phase 1/Phase 2
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Terminated NCT00064259 - A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer Phase 1/Phase 2
Completed NCT00045526 - Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer Phase 2
Not yet recruiting NCT05856500 - A Study of Creatine Combined With Curcumin in the Intervention of Early Cachexia in Upper Gastrointestinal Tumors N/A
Completed NCT01129206 - Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy Phase 2
Active, not recruiting NCT04670445 - Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer N/A
Completed NCT00607594 - Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer Phase 2
Completed NCT00397384 - Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Phase 1
Completed NCT00077545 - 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction Phase 2
Completed NCT01231399 - Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer Phase 1/Phase 2
Completed NCT00030498 - Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Phase 1
Completed NCT00031681 - 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Phase 1
Active, not recruiting NCT03154190 - Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer N/A
Completed NCT00004074 - Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Phase 1